Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398386 | 1.00 | USP2 (0.38) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL1916140 | 1.00 | USP2 (0.38) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL1716814 | 0.95 | USP2 (0.42) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL2399882 | 0.95 | USP2 (0.42) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL2397125 | 0.95 | USP2 (0.42) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL1705698 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL18269631 | 0.79 | USP2 (0.40) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL29191695 | 0.78 | GRIK1 (0.43) | USP2SMN1; SMN2TP53HPGDALOX12 | |
| SCHEMBL1176739 | 0.78 | CA2 (0.42) | USP2ALDH1A1HTR2A | |
| SCHEMBL21218827 | 0.78 | CA2 (0.42) | USP2ALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | USP2 4261/4885SMN1; SMN2 3353/4885TP53 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.